| Overactive Bladder
Detrol LA vs Gemtesa
Side-by-side clinical, coverage, and cost comparison for overactive bladder.Deep comparison between: Detrol La vs Gemtesa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGemtesa has a higher rate of injection site reactions vs Detrol La based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gemtesa but not Detrol La, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Detrol La
Gemtesa
At A Glance
Oral
Once daily
Muscarinic receptor antagonist
Oral
Once daily
Beta-3 adrenergic agonist
Indications
- Overactive Bladder
- Urinary Incontinence
- Overactive Bladder
Dosing
Overactive Bladder, Urinary Incontinence 4 mg orally once daily; reduce to 2 mg once daily for mild to moderate hepatic impairment (Child-Pugh A or B), severe renal impairment (CCr 10-30 mL/min), or concomitant potent CYP3A4 inhibitors; not recommended in severe hepatic impairment (Child-Pugh C) or CCr <10 mL/min.
Overactive Bladder 75 mg tablet orally once daily with or without food; swallow whole with a glass of water, or crush and mix with approximately 15 mL of applesauce and take immediately with water.
Contraindications
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Known hypersensitivity to tolterodine, its ingredients, or fesoterodine fumarate extended-release tablets
- Known hypersensitivity to vibegron or any components of GEMTESA
Adverse Reactions
Most common (>=1%) dry mouth, headache, constipation, abdominal pain, dyspepsia, somnolence, xerophthalmia, fatigue, dizziness, sinusitis, vision abnormal, anxiety, dysuria
Postmarketing anaphylaxis, angioedema, tachycardia, palpitations, peripheral edema, diarrhea, confusion, disorientation, memory impairment, hallucinations
Most common (>=2%) Headache, nasopharyngitis, diarrhea, nausea, upper respiratory tract infection, urinary tract infection, bronchitis
Serious Urinary retention
Postmarketing Urinary retention, angioedema of the face and larynx, hypersensitivity reactions (urticaria, pruritus, rash, drug eruption), eczema, constipation
Pharmacology
Tolterodine is a competitive antagonist of acetylcholine at postganglionic muscarinic receptors; it and its active metabolite 5-hydroxymethyl tolterodine (5-HMT) reduce urinary bladder contraction and overactive bladder symptoms by blocking cholinergic muscarinic signaling.
Vibegron is a selective human beta-3 adrenergic receptor agonist; activation of the beta-3 adrenergic receptor increases bladder capacity by relaxing the detrusor smooth muscle during bladder filling.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Detrol La
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (11/12)
Gemtesa
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Detrol La
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Gemtesa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Detrol La
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Gemtesa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Detrol La.
No savings programs available for Gemtesa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Detrol LaView full Detrol La profile
GemtesaView full Gemtesa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.